Search NLS News

Elicera Therapeutics' drug candidate ELC-100 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic neuroendocrine tumors.

Researchers at the University of Gothenburg, in collaboration with colleagues in China, have discovered an antibody-like molecule that can protect mice from various influenza viruses.

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy.

Diamyd Medical provides an update following the receipt of final meeting minutes from a positive Type C meeting with the U.S. Food and Drug Administration (FDA) held in December 2024.

Enzymatica has announced that Anna Söderlund has joined as the new Senior Director Marketing & Sales.

Alice Long, a leading expert in translational immunology and diabetes research, has joined Diamyd Medical’s Scientific Advisory Board (SAB).

AnaCardio has announced the completion of a USD 19 million Series A extension financing round, co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures. Current investors Flerie, Industrifonden, and Fredrik and Ann-Helene Ljungström, also participated to complete the round.

Novo Nordisk and Valo Health have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s human dataset and computation powered by artificial intelligence (AI).

Stryker has announced a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical for USD 80 per share in cash, representing a total fully diluted equity value of approximately USD 4.9 billion.

PolyPeptide Group has announces the planned doubling of solid-phase peptide synthesis (SPPS) capacity at its manufacturing site in Malmö, Sweden.